Analysis of 3789 in- and outpatient Escherichia coli isolates from across Canada-results of the CANWARD 2007-2009 study

被引:23
作者
Lagace-Wiens, Philippe R. S. [1 ,2 ]
Simner, Patricia J. [2 ]
Forward, Kevin R. [3 ]
Tailor, Franil [2 ]
Adam, Heather J. [2 ,4 ]
DeCorby, Melanie [2 ]
Karlowsky, James [2 ,4 ]
Hoban, Daryl J. [2 ,4 ]
机构
[1] St Boniface Gen Hosp, Dept Microbiol, Diagnost Serv Manitoba, Winnipeg, MB R2H 2A6, Canada
[2] Univ Manitoba, Dept Med Microbiol & Infect Dis, Winnipeg, MB R3E 0J9, Canada
[3] Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS B3H 1X5, Canada
[4] Hlth Sci Ctr, Dept Microbiol, Diagnost Serv Manitoba, Winnipeg, MB R3A 1R9, Canada
关键词
E; coli; Susceptibility; Outpatient; Inpatient; LACTAMASE-PRODUCING ENTEROBACTERIACEAE; ANTIMICROBIAL SUSCEPTIBILITY DATA; URINARY-TRACT-INFECTIONS; RISK-FACTORS; MEDICAL-CENTERS; MYSTIC PROGRAM; SPECTRUM; PREVALENCE; EMERGENCE; BACTERIA;
D O I
10.1016/j.diagmicrobio.2010.10.027
中图分类号
R51 [传染病];
学科分类号
100201 [内科学];
摘要
Escherichia coli was the most commonly isolated pathogen in the Canadian Ward Surveillance Study 2007-2009 (3789 isolates). Susceptibility to cefazolin (34.1%), trimethoprim-sulfamethoxazole (73.8%), ciprofloxacin (78.4%), and levofloxacin (78.8%) was lowest. Susceptibility was above 90% for meropenem (100%), tigecycline (99.9%), piperacillin-tazobactam (97.6%), nitrofurantoin (96.9%), ceftazidime (95.6%), amoxicillin-clavulanate (94.9%), ceftriaxone (94.1%), cefoxitin (92.3%), and gentamicin (90.8%). Over the study period, there was a significant reduction in susceptibility to amoxicillin-clavulanate and trimethoprim-sulfamethoxazole for urinary tract isolates. Inpatient status was associated with greater resistance to nearly all antimicrobials including greater multidrug resistance (MDR). Increasing age was associated with resistance to fluoroquinolones, ceftriaxone, piperacillin-tazobactam, and MDR. Female gender was associated with susceptibility to fluoroquinolones and nitrofurantoin. In conclusion, greater antimicrobial resistance and MDR in E. coli were observed in inpatients, males, and with increasing age. The deterioration of susceptibility to trimethoprim-sulfamethoxazole continues with the greatest reduction in urinary isolates. Significant regional differences in resistance rates were apparent. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:314 / 319
页数:6
相关论文
共 26 条
[1]
[Anonymous], 2009, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically
[2]
Approved Standard, VEighth
[3]
[Anonymous], 2010, CLSI Document M100-S20
[4]
[Anonymous], 2006, METHODS DILUTION ANT, V7th
[5]
A Multinational Survey of Risk Factors for Infection with Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in Nonhospitalized Patients [J].
Ben-Ami, Ronen ;
Rodriguez-Bano, Jesus ;
Arslan, Hande ;
Pitout, Johann D. D. ;
Quentin, Claudine ;
Calbo, Esther S. ;
Azap, Oezlem K. ;
Arpin, Corinne ;
Pascual, Alvaro ;
Livermore, David M. ;
Garau, Javier ;
Carmeli, Yehuda .
CLINICAL INFECTIOUS DISEASES, 2009, 49 (05) :682-690
[6]
Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients [J].
Colodner, R ;
Rock, W ;
Chazan, B ;
Keller, N ;
Guy, N ;
Sakran, W ;
Raz, R .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2004, 23 (03) :163-167
[7]
Prevalence and antimicrobial susceptibility data for extended-spectrum β-lactamase- and AmpC-producing Enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997-2004) [J].
Goossens, H ;
Grabein, B .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2005, 53 (04) :257-264
[8]
Introduction to the CANWARD Study (2007-2009) [J].
Hoban, Daryl J. ;
Zhanel, George G. .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2011, 69 (03) :289-290
[9]
Epidemic Clonal Groups of Escherichia coli as a Cause of Antimicrobial-Resistant Urinary Tract Infections in Canada, 2002 to 2004 [J].
Johnson, James R. ;
Menard, Megan ;
Johnston, Brian ;
Kuskowski, Michael A. ;
Nichol, Kim ;
Zhanel, George G. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (07) :2733-2739
[10]
Johnston M, 2000, J R SOC PROMO HEALTH, V120, P81